Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials
- 31 August 1999
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 117 (2), 408-413
- https://doi.org/10.1053/gast.1999.0029900408
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis CNew England Journal of Medicine, 1998
- Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virusThe Lancet, 1998
- Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patientsJournal of Hepatology, 1998
- Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis CThe Lancet, 1998
- Therapy of hepatitis C: Consensus interferon trialsHepatology, 1997
- Therapy of hepatitis C: Patients with cirrhosisHepatology, 1997
- Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: Meta-analysis of individual patient data from European centersJournal of Hepatology, 1997
- Ribavirin and interferon‐α combination therapy vs interferon‐α alone in the retreatment of chronic hepatitis C: a randomized clinical trialJournal of Viral Hepatitis, 1997
- Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis CGastroenterology, 1996
- What options are left when hepatitis C does not respond to interferon? Placebo-controlled benelux multicentre retreatment trial on ribavirin monotherapy versus combination with interferonJournal of Hepatology, 1994